MYND Life Sciences Inc.
MYND
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -399.00K | -519.90K | -784.60K | -1.13M | -1.89M |
| Total Depreciation and Amortization | 1.80K | 2.40K | 7.70K | 15.60K | 23.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -682.40K | -547.60K | -439.10K | -327.70K | 244.50K |
| Change in Net Operating Assets | 952.20K | 900.50K | 1.03M | 1.30M | 1.64M |
| Cash from Operations | -127.40K | -164.60K | -185.20K | -146.50K | 15.60K |
| Capital Expenditure | 0.00 | -1.00K | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -13.70K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 164.30K | 164.30K | 164.30K | 164.30K | -- |
| Other Investing Activities | 0.00 | 1.00K | -7.40K | -18.50K | -29.80K |
| Cash from Investing | 164.30K | 164.30K | 156.90K | 145.80K | -43.50K |
| Total Debt Issued | -- | -- | -- | -- | -11.70K |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 50.00K | 50.00K | 50.00K | 50.00K |
| Repurchase of Common Stock | -50.00K | -50.00K | -50.00K | -50.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -36.80K | 700.00 | 700.00 | 700.00 | 28.70K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.00 | 500.00 | -27.60K | 0.00 | 900.00 |